Common use of The Principal Investigator Clause in Contracts

The Principal Investigator. 5.1. Xxxxxxxxx Xxxxxxx Ami Sidi, MD of the Medical Center (hereinafter: “the Principal Investigator”) has agreed to serve as the principal investigator of the Trial 5.2. The Principal Investigator undertakes to perform the Trial in compliance with the following: (a) the Trial Protocol, (b) the Guidelines, (c) the instructions and the terms specified in the approval of the Medical Center Helsinki Committee, (d) the ICH-GCP, (e) the Helsinki Declaration, (f) the applicable laws, rules and regulations regulating such studies which are applicable in Israel, (g) written instructions and prescriptions issued by BioCancell regarding the Trial and/or the Product; all as may be amended from time to time, and (h). the requirements in accordance with the FDA Form 1572 “Statement of Investigator.” Every PI at each site must sign this form for submission to the FDA 5.3. The Principal Investigator has declared that he holds the professional ability and credentials required for performing the Trial in accordance with the Trial Protocol and any applicable laws, rules, regulations and guidelines, all as detailed above. 5.4. In the event that the Principal Investigator, for any reason whatsoever, shall be unable to conduct the Trial, or shall cease to be available for the performance of the undertakings set forth in this Agreement, the Medical Center shall use its best efforts to appoint, within 20 days, a successor investigator whose identity shall be approved in advance by BioCancell (the “Successor Investigator”). Such Successor Investigator shall undertake all the duties and responsibilities of the Principal Investigator as detailed in the Agreement. Should the Medical Center not be able to appoint a Successor Investigator, or if the appointed Successor Investigator is not acceptable by BioCancell, either party shall be entitled to terminate this Agreement forthwith and without further liability. 5.5. In the event of the replacement of the Principal Investigator, as described under this Section 5, the Principal Investigator shall have no claim towards BioCancell and/or the Medical Center and/or any third party acting on their behalf in direct or indirect connection with such replacement. Template - agreement with medical centers

The Principal Investigator. 5.1. Xxxxxxxxx Xxxxxxx Ami SidiXx. Xxxx Xxxxxxxxxx MD, MD of the Medical Center (hereinafter: “the Principal Investigator”) has agreed to serve as the principal investigator of the Trial. 5.2. The Principal Investigator undertakes to perform the Trial in compliance with the following: (a) the Trial Protocol, (b) the Guidelines, (c) the instructions and the terms specified in the approval of the Medical Center Helsinki Committee, (d) the ICH-GCP, (e) the Helsinki Declaration, (f) the applicable laws, rules and regulations regulating such studies which are applicable in Israel, (g) written instructions and prescriptions issued by BioCancell regarding the Trial and/or the Product; , all as may be amended from time to time, and (h). ) the requirements in accordance with the FDA Form 1572 “Statement of Investigator.” Every PI at each site must sign this form for submission to the FDA. 5.3. The Principal Investigator has declared that he holds the professional ability and credentials required for performing the Trial in accordance with the Trial Protocol and any applicable laws, rules, regulations and guidelines, all as detailed above. 5.4. In the event that the Principal Investigator, for any reason whatsoever, shall be unable to conduct the Trial, or shall cease to be available for the performance of the undertakings set forth in this Agreement, the Medical Center shall use its best efforts to appoint, within 20 days, a successor investigator whose identity shall be approved in advance by BioCancell (the “Successor Investigator”). Such Successor Investigator shall undertake all the duties and responsibilities of the Principal Investigator as detailed in the Agreement. Should the Medical Center not be able to appoint a Successor Investigator, or if the appointed Successor Investigator is not acceptable by BioCancell, either party shall be entitled to terminate this Agreement forthwith and without further liability. 5.5. In the event of the replacement of the Principal Investigator, as described under this Section 5, the Principal Investigator shall have no claim towards BioCancell and/or the Medical Center and/or any third party acting on their behalf in direct or indirect connection with such replacement. Template - Meir-final agreement with medical centers0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: +000-0-000-0000 Fax: +000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx

The Principal Investigator. 5.1. Xxxxxxxxx Xxxxxxx Ami SidiXx. Xxxxxxxx Xxxxxx MD, MD of the Medical Center HMO (hereinafter: “the Principal Investigator”) has agreed to serve as the principal investigator of the Trial. 5.2. The Principal Investigator undertakes to perform the Trial in compliance with the following: (a) the Trial Protocol, (b) the Guidelines, (c) the instructions and the terms specified in the approval of the Medical Center Helsinki Committee, (d) the ICH-GCP, (e) the Helsinki Declaration, (f) the applicable laws, rules and regulations regulating such studies which are applicable in Israel, (g) written instructions and prescriptions issued by BioCancell regarding the Trial and/or the Product; all as may be amended from time to time, and (h). ) the requirements in accordance with the FDA Form 1572 “Statement of Investigator.” Every PI at each site must sign this form for submission to the FDA. Hadassah–agreement 0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: +000-0-000-0000 Fax: +000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx 5.3. The Principal Investigator has declared that he holds the professional ability and credentials required for performing the Trial in accordance with the Trial Protocol and any applicable laws, rules, regulations and guidelines, all as detailed above. 5.4. In the event that the Principal Investigator, for any reason whatsoever, shall be unable to conduct the Trial, or shall cease to be available for the performance of the undertakings set forth in this Agreement, the Medical Center shall use its best efforts to appoint, within 20 days30 days of the Investigator becoming unable to conduct the Trial, a suitably qualified successor investigator whose identity shall be approved in advance by BioCancell (the “Successor Investigator”). Such Successor Investigator shall undertake all the duties and responsibilities of the Principal Investigator as detailed in the Agreement. Should the Medical Center not be able to appoint a Successor Investigator, or if the appointed Successor Investigator is not acceptable by BioCancell, either party shall be entitled to terminate this Agreement forthwith and without further liabilityliability and at no cost to Biocancell, save for any payments for work already performed and for documented out-of-pocket costs arising from non-cancellable commitments incurred prior to such termination. 5.5. In the event of the replacement of the Principal Investigator, as described under this Section 55.4, the Principal Investigator shall have no claim towards BioCancell and/or the Medical Center and/or any third party acting on their behalf in direct or indirect connection with such replacement. Template - agreement with medical centers.

The Principal Investigator. 5.1. Xxxxxxxxx Xxxxxxx Ami SidiXx. Xxxxxx Xxxxxx, MD of the Medical Center (hereinafter: “the Principal Pricipal Investigator”) has agreed to serve as the principal investigator of the Trial 5.2. The Principal Investigator undertakes to perform the Trial in compliance with the following: (a) the Trial Protocol, (b) the Guidelines, (c) the instructions and the terms specified in the approval of the Medical Center Helsinki Committee, (d) the ICH-GCP, (e) the Helsinki Declaration, (f) the applicable laws, rules and regulations regulating such studies which are applicable in Israel, (g) written instructions and prescriptions issued by BioCancell regarding the Trial and/or the Product; all as may be amended from time to time, and (h). the requirements in accordance with the FDA Form 1572 “Statement of Investigator.” Every PI at each site must sign this form for submission to the FDA 5.3. The Principal Investigator has declared that he holds the professional ability and credentials required for performing the Trial in accordance with the Trial Protocol and any applicable laws, rules, regulations and guidelines, all as detailed above. 5.4. In the event that the Principal Investigator, for any reason whatsoever, shall be unable to conduct the Trial, or shall cease to be available for the performance of the undertakings set forth in this Agreement, the Medical Center shall use its best efforts to appoint, within 20 days, a successor investigator whose identity shall be approved in advance by BioCancell (the “Successor Investigator”). Such Successor Investigator shall undertake all the duties and responsibilities of the Principal Investigator as detailed in the Agreement. Should the Medical Center not be able to appoint a Successor Investigator, or if the appointed Successor Investigator is not acceptable by BioCancell, either party shall be entitled to terminate this Agreement forthwith and without further liability. 5.5. In the event of the replacement of the Principal Investigator, as described under this Section 5, the Principal Investigator shall have no claim towards BioCancell and/or the Medical Center and/or any third party acting on their behalf in direct or indirect connection with such replacement. Template - – agreement with medical centers

The Principal Investigator. 5.1. Xxxxxxxxx Xxxxxxx Ami SidiXxxxx X. Xxxxx MD, MD PhD of the Medical Center (hereinafter: “the Principal Investigator”) has agreed to serve as the principal investigator of the Trial 5.2. The Principal Investigator undertakes to perform the Trial in compliance with the following: (a) the Trial Protocol, (b) the Guidelines, (c) the instructions and the terms specified in the approval of the Medical Center Helsinki Committee, (d) the ICH-GCP, (e) the Helsinki Declaration, (f) the applicable laws, rules and regulations regulating such studies which are applicable in Israel, (g) written instructions and prescriptions issued by BioCancell regarding the Trial and/or the Product; all as may be amended from time to time, and (h). the requirements in accordance with the FDA Form 1572 “Statement of Investigator.” Every PI at each site must sign this form for submission to the FDA 5.3. The Principal Investigator has declared that he holds the professional ability and credentials required for performing the Trial in accordance with the Trial Protocol and any applicable laws, rules, regulations and guidelines, all as detailed above. 5.4. In the event that the Principal Investigator, for any reason whatsoever, shall be unable to conduct the Trial, or shall cease to be available for the performance of the undertakings set forth in this Agreement, the Medical Center Fund shall use its best efforts to appoint, within 20 days, a successor investigator whose identity shall be approved in advance by BioCancell (the “Successor Investigator”). Such Successor Investigator shall undertake all the duties and responsibilities of the Principal Investigator as detailed in the Agreement. Should the Medical Center Fund not be able to appoint a Successor Investigator, or if the appointed Successor Investigator is not acceptable by BioCancell, either party shall be entitled to terminate this Agreement forthwith and without further liability. 5.5. In the event of the replacement of the Principal Investigator, as described under this Section 5, the Principal Investigator shall have no claim towards BioCancell and/or the Medical Center Fund and/or any third party acting on their behalf in direct or indirect connection with such replacement. Template - agreement with medical centers.

The Principal Investigator. 5.1. Xxxxxxxxx Xxxxxxx Ami SidiXx. Xxxxx Xxxxxxxx MD, MD of the Medical Center (hereinafter: “the Principal Investigator”) has agreed to serve as the principal investigator of the Trial 5.2. The Principal Investigator undertakes to perform the Trial in compliance with the following: (a) the Trial Protocol, (b) the Guidelines, (c) the instructions and the terms specified in the approval of the Medical Center Helsinki Committee, (d) the ICH-GCP, (e) the Helsinki Declaration, (f) the applicable laws, rules and regulations regulating such studies which are applicable in Israel, (g) written instructions and prescriptions issued by BioCancell regarding the Trial and/or the Product; all as may be amended from time to time, and (h). ) the requirements in accordance with the FDA Form 1572 “Statement of Investigator.” Every PI at each site must sign this form for submission to the FDA 5.3. The Principal Investigator has declared that he holds the professional ability and credentials required for performing the Trial in accordance with the Trial Protocol and any applicable laws, rules, regulations and guidelines, all as detailed above. 5.4. In the event that the Principal Investigator, for any reason whatsoever, shall be unable to conduct the Trial, or shall cease to be available for the performance of the undertakings set forth in this Agreement, the Medical Center shall use its best efforts to appoint, within 20 days, a successor investigator whose identity shall be approved in advance by BioCancell (the “Successor Investigator”). Such Successor Investigator shall undertake all the duties and responsibilities of the Principal Investigator as detailed in the Agreement. Should the Medical Center not be able to appoint a Successor Investigator, or if the appointed Successor Investigator is not acceptable by BioCancell, either party shall be entitled to terminate this Agreement forthwith and without further liability.. Bnai Zion – final agreement 5.5. In the event of the replacement of the Principal Investigator, as described under this Section 5, the Principal Investigator shall have no claim towards BioCancell and/or the Medical Center and/or any third party acting on their behalf in direct or indirect connection with such replacement. Template - agreement with medical centers.